Coordination between TGF-β cellular signaling and epigenetic regulation during epithelial to mesenchymal transition

• Main Authors: Congcong Lu, Simone Sidoli, Katarzyna Kulej, Karen Ross, Cathy H. Wu, Benjamin A. Garcia
• Format: Article
• Language: English
• Published: BMC 2019-02-01
• Series: Epigenetics & Chromatin
• Subjects: Epithelial to mesenchymal transition; Time-resolved quantitative (phospho)proteomics; Comprehensive profiling of histone modifications; Erk signaling; Histone H3 lysine 27 trimethylation; Combinatorial inhibition targeting signaling pathway and epigenetic regulator
• Online Access: http://link.springer.com/article/10.1186/s13072-019-0256-y

Abstract Background Epithelial to mesenchymal transition (EMT) plays a crucial role in cancer propagation. It can be orchestrated by the activation of multiple signaling pathways, which have been found to be highly coordinated with many epigenetic regulators. Although the mechanism of EMT has been studied over decades, cross talk between signaling and epigenetic regulation is not fully understood. Results Here, we present a time-resolved multi-omics strategy, which featured the identification of the correlation between protein changes (proteome), signaling pathways (phosphoproteome) and chromatin modulation (histone modifications) dynamics during TGF-β-induced EMT. Our data revealed that Erk signaling was activated in 5-min stimulation and structural proteins involved in cytoskeleton rearrangement were regulated after 1-day treatment, constituting a detailed map of systematic changes. The comprehensive profiling of histone post-translational modifications identified H3K27me3 as the most significantly up-regulated mark. We thus speculated and confirmed that a combined inhibition of Erk signaling and Ezh2 (H3K27me3 methyltransferase) was more effective in blocking EMT progress than individual inhibitions. Conclusions In summary, our data provided a more detailed map of cross talk between signaling pathway and chromatin regulation comparing to previous EMT studies. Our findings point to a promising therapeutic strategy for EMT-related diseases by combining Erk inhibitor (singling pathway) and Ezh2 inhibitor (epigenetic regulation).